Stem cell manufacturing market seen reaching $55.9B by 2035

Market Research Future projects the global stem cell manufacturing market will grow from $20.54 billion in 2026 to $55.92 billion by 2035, driven by a swelling cell and gene therapy pipeline, adoption of closed-system bioreactors and tighter global regulation. The report points to rising demand across therapeutics, banking, and contract manufacturing as commercial production scales.

Why it matters: - Stem cell manufacturing is shifting from a research niche to a commercial bioproduction market tied to cell and gene therapy scale-up. - The market's projected growth suggests more demand for GMP-grade inputs, automated production systems and contract manufacturing capacity. - Regulatory alignment across major markets could make it easier for manufacturers to standardize processes and expand internationally.

What happened: - Market Research Future projected the global stem cell manufacturing market will rise from USD 20.54 billion in 2026 to USD 55.92 billion by 2035. - The forecast implies an 11.8% compound annual growth rate from 2026 through 2035. - The market was estimated at USD 18.22 billion in 2025. - The report was published July 13, 2026. - The report includes a free sample request, a customization request and the full market report.

The details: - The growth case is anchored by more than 3,700 active investigational new drug applications for cell and gene therapy products reported by the FDA's Center for Biologics Evaluation and Research as of mid-2024. - That total was more than triple the 2019 level. - Late-stage cell therapy candidates need GMP-grade stem cell inputs at volumes that manual production lines struggle to supply. - Catalent, Lonza and Samsung Biologics announced about USD 1.8 billion in cell therapy capacity investments between 2023 and 2025. - Closed-system bioreactors are replacing open-vessel, flask-based culture systems. - A 2024 ISCT benchmarking study found automated closed systems can cut contamination episodes by as much as 40% and operator touch-points by 60%. - A single lost batch can cost USD 500,000 to USD 2 million in wasted material and labor. - Japan's 2024 revision of the Act on the Safety of Regenerative Medicine created a quality framework for both autologous and allogeneic cell products. - That change has triggered reciprocal policy reviews in South Korea, Australia and the EU. - The EMA updated guidance on ATMP manufacturing in early 2024. - China's NMPA finalized its cell therapy clinical trial registration pathway in late 2024.

Between the lines: - The forecast reflects a broader shift from academic supply toward industrial-scale therapeutic manufacturing. - Automation is becoming a cost-control strategy as much as a quality strategy. - Regulatory convergence matters because it lowers the friction for global sponsors that want to use similar production standards across multiple facilities. - The report also signals that market power is concentrating around integrated suppliers and large CDMOs rather than standalone reagent vendors.

What's next: - Consumables should remain the largest product segment because every production run requires reagents, vessels, kits and cryopreservation materials. - Instruments are expected to be the fastest-growing product class as manufacturers buy bioreactors, cell counters, flow cytometers and automated fill-finish systems. - Stem cell therapy is projected to stay the largest application, supported by more than 2,000 active stem cell-based clinical trials in 2024. - Stem cell banking is forecast to grow fastest as private cord blood registrations expand and operators add cord tissue and placental storage. - Pharma and biotech companies are expected to remain the largest end-user group, while contract manufacturing organizations continue to gain share as outsourcing rises. - Market Research Future's outlook points to AI-augmented bioprocess control and CDMO consolidation becoming more important through 2035.

The bottom line: - Stem cell manufacturing is moving into a higher-volume, more automated and more regulated phase, and the companies that can combine scale, closed systems and compliant quality controls are positioned to benefit most.